等待开盘 11-18 09:30:00 美东时间
0.000
0.00%
Esperion, a wholly-owned subsidiary of ARCHIMED, has settled patent litigation with Aurobindo Pharma over generic versions of NEXLETOL and NEXLIZET. Under the agreement, Aurobindo will not market generics in the U.S. until April 19, 2040, barring exceptional circumstances. Litigation against other defendants, MSN Pharmaceuticals and Sandoz, continues. Esperion, a biopharmaceutical company focused on cardiometabolic therapies, markets two non-stat...
11-10 13:44
MiMedx Group announced that its senior management will participate in two investor conferences: the Canaccord MedTech, Diagnostics and Digital Health & Services Forum in New York on November 11, 2026, and the Craig-Hallum 17th Annual Alpha Select Conference in New York on November 17, 2026. The company, a leader in wound care solutions, invites investors to contact Canaccord or Craig-Hallum representatives for meetings. MiMedx aims to be the lead...
11-06 13:00
ARCHIMED has completed its acquisition of Standard BioTools' Microfluidics Business, renaming it Biomark Scientific. As a leader in genomic workflows, Biomark Scientific leverages proprietary microfluidics technology to offer scalable and automated solutions, including the next-generation Biomark X9 system. The company, previously part of Fluidigm, will expand its capabilities under ARCHIMED's support, focusing on genomics, clinical research, and...
11-03 12:30
MPT 2026年第三季度业绩电话会议:随着再融资取得进展,归一化运营资金(FFO)为每股0.11美元,而HSA租金和Priory的租赁协议修订仍是关键问题。
10-29 20:11
MPT Q3 2026 earnings call: normalized FFO was $0.11 per share as refinancing advanced, while HSA rent and Priory’s lease revision remained key issues.
10-29 20:06
MiMedx Group has entered into a $25 million license agreement with a wound care competitor, resolving patent infringement allegations. The licensee will pay $5 million annually over five years, with the first installment received. MiMedx granted a non-exclusive license to its patents. The agreement highlights the company's strong intellectual property portfolio and innovation in placental biologics. MiMedx will continue to protect its IP while in...
10-28 20:01
MiMedx Group announced it will report its third-quarter 2026 results on October 28, 2026, after market close. A webcast and conference call to review the results will begin at 4:30 p.m. ET the same day. U.S. Investors can join via 877-407-6184, international investors via 201-389-0877, using Conference ID 13762954. A replay will be available for 30 days on www.mimedx.com. MiMedx is a leader in wound care solutions, aiming to be the global leader ...
10-14 20:01
Standard BioTools (LAB) announced Monday it has entered into a definitive agreement to sell its Microfluidics business to ARCHIMED, an investment firm focused exclusively on healthcare industries. The...
10-06 04:15
iRadimed (IRMD) declares $0.20/share quarterly dividend, in line with previous. Forward yield 0.88% Payable Aug. 28; for shareholders of record Aug. 14; ex-div Aug. 14. See IRMD Dividend Scorecard, Yi...
08-03 12:37